Fulgent Genetics (Fulgent Genetics) Net-Net Working Capital : $12.35 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Fulgent Genetics's Net-Net Working Capital for the quarter that ended in Dec. 2023 was $12.35.

The industry rank for Fulgent Genetics's Net-Net Working Capital or its related term are showing as below:

FLGT's Price-to-Net-Net-Working-Capital is ranked better than
82.69% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 5.79 vs FLGT: 1.65

Fulgent Genetics Net-Net Working Capital Historical Data

The historical data trend for Fulgent Genetics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Net-Net Working Capital Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net-Net Working Capital

Get a 7-Day Free Trial

1.27

11.16

14.62

15.24

12.35

Fulgent Genetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net-Net Working Capital	Get a 7-Day Free Trial															15.24	14.39	13.12	13.57	12.35

Competitive Comparison of Fulgent Genetics's Net-Net Working Capital

For the Diagnostics & Research subindustry, Fulgent Genetics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's Price-to-Net-Net-Working-Capital Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Price-to-Net-Net-Working-Capital falls into.

Fulgent Genetics Net-Net Working Capital Calculation

Fulgent Genetics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

	Net-Net Working Capital		(A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(424.154	+	0.75 * 51.132	+	0.5 * 5.827	-	102.042
-	0	-	-2.815)	/	29.653
=	12.35

Fulgent Genetics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

	Net-Net Working Capital		(Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(424.154	+	0.75 * 51.132	+	0.5 * 5.827	-	102.042
-	0	-	-2.815)	/	29.653
=	12.35

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Fulgent Genetics (NAS:FLGT) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Fulgent Genetics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (Fulgent Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

7F0:Germany 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Executives

Jian Xie	officer: Chief Operating Officer	C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao	10 percent owner, officer: Chief Scientific Officer	4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim	officer: CFO and Treasurer	4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post	director
Michael Nohaile	director	C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger	director	4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust	10 percent owner	4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh	director	100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh	director, 10 percent owner, officer: President and CEO	4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc.	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay	director	6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc.	10 percent owner	#6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663